University of Oulu

Zagotta I, Dimova EY, Debatin K-M, Wabitsch M, Kietzmann T and Fischer-Posovszky P (2015) Obesity and inflammation: reduced cytokine expression due to resveratrol in a human in vitro model of inflamed adipose tissue. Front. Pharmacol. 6:79. doi: 10.3389/fphar.2015.00079

Obesity and inflammation : reduced cytokine expression due to resveratrol in a human in vitro model of inflamed adipose tissue

Saved in:
Author: Zagotta, Ivana1; Dimova, Elitsa Y.2; Debatin, Klaus-Michael3;
Organizations: 1Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany
2Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, Oulu, Finland
3Department of Pediatric and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 2 MB)
Persistent link:
Language: English
Published: Frontiers Media, 2015
Publish Date: 2017-03-15


Obesity is associated with an inflammatory status and linked with a number of pathophysiological complications among them cardiovascular disease, type 2 diabetes mellitus, or the metabolic syndrome. Resveratrol was proposed to improve obesity-related inflammatory problems, but the effect of resveratrol on cytokine expression in obesity is not completely understood. In this study, we used an in vitro model of human adipose tissue inflammation to examine the effects of resveratrol on the production of the inflammatory cytokines interleukin 6 (IL-6), IL-8, and monocyte chemoattractant protein 1 (MCP-1). We found that resveratrol reduced IL-6, IL-8, and MCP-1 levels in a concentration-dependent manner in adipocytes under inflammatory conditions. Further experiments showed that the action of resveratrol was mainly due to its NFκB inhibitory potential. Thus, our data support the concept that resveratrol can alleviate obesity-induced up-regulation of inflammatory cytokines providing a new insight toward novel treatment options in obesity.

see all

Series: Frontiers in pharmacology
ISSN: 1663-9812
ISSN-E: 1663-9812
ISSN-L: 1663-9812
Volume: 6
Article number: 79
DOI: 10.3389/fphar.2015.00079
Type of Publication: A1 Journal article – refereed
Field of Science: 1182 Biochemistry, cell and molecular biology
Funding: PF-P was funded by a Margarete von Wrangell scholarship financed by the Baden-Wuerttemberg Ministry of Science, Research and Arts, the European Social Fund, and Ulm University. IZ is funded by the International Gradute School in Molecular Medicine Ulm. This study was in part supported by the foundation “Das zuckerkranke Kind” to PF-P. Work in the TK lab is supported by grants from the Biocenter Oulu, Academy of Finland and Sigrid Juselius Foundation.
Copyright information: Copyright © 2015 Zagotta, Dimova, Debatin, Wabitsch, Kietzmann and Fischer-Posovszky. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.